

# Content

Summary English .....	3
Abbreviations .....	7
<b>1 Introduction .....</b>	<b>8</b>
1.1 Preface .....	8
1.2 History and Facts on the Thomsen-Friedenreich Antigen .....	10
1.2.1 Structure and synthesis of TF .....	10
1.2.2 Detection of TF and its establishment as tumour specific antigen .....	12
1.2.3 Potential applications of TF in the clinic .....	13
1.3 Antibodies .....	15
1.3.1 Recombinant antibody fragments .....	15
1.3.2 Multimerisation .....	17
1.3.2.1 Fusion-derived multimers .....	17
1.3.2.2 Antibody-derived structures .....	17
1.3.2.3 ScFv multimers .....	18
1.3.2.4 Single-chain diabodies .....	18
1.3.2.5 Recombinant antibodies in clinical trials .....	19
1.3.3 Generation of scFv antibodies .....	19
1.3.3.1 Morphology and life cycle of the filamentous bacteriophage Ff .....	19
1.3.3.2 Display on phage particles .....	21
1.3.3 Humanised Antibodies .....	23
<b>2 Results .....</b>	<b>25</b>
2.1 Selection of TF-specific antibodies by phage display .....	25
2.1.1 Semi-synthetic scFv libraries, Griffin.1, TomlinsonI and TomlinsonJ .....	26
2.1.2 scFv libraries from colorectal carcinoma patients .....	26
2.1.2.1 Generation of scFv libraries from colorectal carcinoma patients .....	27
2.1.2.2 Selection of scFv libraries from colorectal carcinoma patients .....	27
2.1.3 Generation of scFv libraries from immunised mice .....	28
2.1.3.1 Generation of scFv libraries from immunised mice .....	28
2.1.3.2 Selection of scFv libraries from immunised mice .....	29
2.2 Characterisation of different scFv formats on phage particles .....	30
2.2.1 Effect of linker length on activity of phage displayed-scFvs .....	30
2.2.2 Investigation of displayed scFvs .....	31
2.3 scFv expression, purification and characterisation .....	33
2.3.1 Optimisation of bacterial protein expression .....	33
2.3.1.1 Purification of insoluble protein .....	34
2.3.1.2 Optimisation of cultivation conditions .....	35
2.3.2 Protein purification .....	36
2.3.2.1 Immobilised metal affinity chromatography (IMAC) .....	36
2.3.2.2 Summary of yields in scFv preparations .....	39
2.3.3 Protein characterisation .....	39
2.3.3.1 Extensive analysis of the fine-specificity of the scFv(1aa) in ELISA .....	39
2.3.3.2 Analysis of the specificity of clone 4F1 .....	41
2.3.3.3 Immunocytochemistry with the scFv(1aa) .....	41
2.3.3.4 Immunohistology of human colon carcinoma with the scFv(1aa) .....	43
2.3.3.5 Size exclusion chromatography .....	43
2.3.3.6 Real time binding kinetics .....	45
2.3.3.7 Anion exchange chromatography (AEC) .....	48
2.3.3.8 Affinity chromatography (AC) .....	50

2.4	Alternative formats for multimerisation of scFvs .....	53
2.4.1	Generation of scDiabody repertoire .....	53
2.4.2	Multimerisation strategies by domain fusion .....	55
2.5	Affinity maturation .....	55
2.5.1	Generation of secondary libraries .....	55
2.5.2	Selection of secondary libraries .....	56
2.6	Generation and evaluation of a radiotherapeutic candidate .....	58
2.6.1	Conjugation of diethylenetriaminepentaacetic acid (DTPA) to scFvs .....	59
2.6.1.1	Titration of DTPA in conjugation of the scFv(1aa) .....	59
2.6.1.2	Binding activity of the scFv – effect of different buffers .....	60
2.6.1.3	Preparation of DTPA-conjugated scFvs .....	61
2.6.1.4	Labelling .....	64
2.6.2	Analysis of the <sup>111</sup> In labelled scFvs .....	64
2.6.2.1	Size exclusion chromatography .....	65
2.6.2.2	Radioimmunoassay (RIA) .....	65
2.6.2.3	Cell bindings .....	66
2.6.2.4	Stability of the <sup>111</sup> In labelled scFvs .....	69
2.6.3	Biodistribution .....	70
2.6.3.1	Biodistribution in healthy mice .....	70
2.6.3.2	Biodistribution in nude mice bearing colorectal carcinoma xenografts .....	71
2.6.3.3	Biodistribution in nude mice bearing ZR-75-1 xenografts .....	72
<b>3</b>	<b>Discussion .....</b>	<b>75</b>
3.1	TF as a therapeutic target .....	75
3.2	Radioimmunotherapy with recombinant antibodies .....	76
3.3	Generation of a TF-specific scFv .....	80
3.4	Specificity of selected scFv .....	83
3.5	Protein production and purification .....	84
3.6	Affinities of the scFvs .....	86
3.7	Radioactive labelling of scFv .....	88
3.8	Biodistributions .....	89
3.9	Potential strategies for optimising the antibody .....	95
3.10	Potential novel applications of a TF-specific scFv .....	97
3.11	Achievements and outlook .....	99
<b>4</b>	<b>Materials and Methods .....</b>	<b>102</b>
4.1	General materials .....	102
4.1.1	Antigens .....	102
4.1.2	Phage .....	102
4.1.3	Bacteria .....	102
4.1.4	Cell lines .....	102
4.1.5	Vectors .....	103
4.1.6	Primers .....	103
4.1.7	Antibodies .....	104
4.2	Phage display protocols .....	105
4.2.1	Phage amplification and precipitation .....	105
4.2.2	Selection .....	105
4.2.3	Phage screening .....	106
4.3	Cloning .....	106
4.3.1	Sequencing .....	106
4.3.2	Library construction from human donors .....	106
4.3.3	Construction of scFv libraries from immunised mice .....	107
4.3.4	Construction of secondary libraries .....	107
4.3.5	Construction of multimers .....	107

4.4	Protein expression and purification.....	108
4.4.1	Expression and harvesting.....	108
4.4.2	Immobilised Metal Affinity Chromatography (IMAC) .....	108
4.4.3	Anion Exchange Chromatography (AEC) .....	109
4.4.4	Affinity chromatography (AC).....	109
4.4.5	Size exclusion chromatography .....	109
4.5	Protein characterisation assays.....	109
4.5.1	ELISA .....	109
4.5.2	Western blots.....	110
4.5.3	Surface plasmon resonance studies .....	110
4.5.4	Immunocytology .....	110
4.5.5	Immunohistology .....	111
4.6	Radioactivity assays.....	111
4.6.1	Labelling .....	111
4.6.2	RIA .....	111
4.6.3	Cell binding.....	112
4.6.4	Biodistribution.....	112
<b>Appendix .....</b>		<b>113</b>
	Scatchard analysis.....	113
	Dissociation.....	113
	Lindmo 114	
<b>Acknowledgement.....</b>		<b>115</b>
<b>CURRICULUM VITAE .....</b>		<b>116</b>
<b>References .....</b>		<b>118</b>
<b>Summary – German.....</b>		<b>135</b>